<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03798197</url>
  </required_header>
  <id_info>
    <org_study_id>MIT-Do001-C101</org_study_id>
    <secondary_id>2018-003761-34</secondary_id>
    <nct_id>NCT03798197</nct_id>
  </id_info>
  <brief_title>Effect of Food on the Bioavailability of 30 mg Estetrol (E4) Tablet in Healthy Postmenopausal Female Volunteers</brief_title>
  <official_title>An Open-label, Single-center, Randomized, Two Period, Two Sequence Crossover Study to Characterize the Effect of Food on the Bioavailability of 30 mg Estetrol (E4) Tablet in Healthy Postmenopausal Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Donesta Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Donesta Bioscience</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the effect of a high fat meal on the quantity in blood of a female sex hormone
      called estetrol (E4).

      The study also aims at determining how subject tolerate the study drug and how safe it is for
      them.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Actual">April 6, 2019</completion_date>
  <primary_completion_date type="Actual">April 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) of Estetrol in plasma</measure>
    <time_frame>Predose, 10, 20, 30, 45 min, 1, 1.25, 1.5, 1.75, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose</time_frame>
    <description>PK sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from time zero to the last determinable concentration of Estetrol</measure>
    <time_frame>Predose, 10, 20, 30, 45 min, 1, 1.25, 1.5, 1.75, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose</time_frame>
    <description>PK sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of Estetrol</measure>
    <time_frame>Predose, 10, 20, 30, 45 min, 1, 1.25, 1.5, 1.75, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose</time_frame>
    <description>PK sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of Cmax (Tmax)</measure>
    <time_frame>Predose, 10, 20, 30, 45 min, 1, 1.25, 1.5, 1.75, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose</time_frame>
    <description>PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal phase rate constant (ke)</measure>
    <time_frame>Predose, 10, 20, 30, 45 min, 1, 1.25, 1.5, 1.75, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose</time_frame>
    <description>PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>Predose, 10, 20, 30, 45 min, 1, 1.25, 1.5, 1.75, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose</time_frame>
    <description>PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events as measure of safety and tolerability</measure>
    <time_frame>From Day 28 prior screening to end of study (Day 4 of Period 2)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Food-effect</condition>
  <arm_group>
    <arm_group_label>30 mg estetrol (E4) without food (fasted)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment A (reference): One 30 mg E4 tablet administered orally following an overnight fast of at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg estetrol (E4) with food (fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B (test): One 30 mg E4 tablet administered orally 30 min after the start of an FDA prescribed high-fat breakfast preceded by at least a 10 hours overnight fast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg estetrol (E4)</intervention_name>
    <description>All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).</description>
    <arm_group_label>30 mg estetrol (E4) with food (fed)</arm_group_label>
    <arm_group_label>30 mg estetrol (E4) without food (fasted)</arm_group_label>
    <other_name>30 mg E4 tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy postmenopausal females as determined by medical history, physical
             examination including breast examination, gynecological examination, cervical smear
             (Pap smear) if subject has cervix, vital signs, and laboratory tests performed within
             28 days before first study drug intake.

          -  Between the ages of 40 and 65 years inclusive at the time of signing the informed
             consent (IC).

          -  Between the Body Mass Index (BMI) of 18 and 30 kg/m2 inclusive and body weight ≥ 45
             kg.

          -  For non-hysterectomized women: intact uterus with bi-layer endometrial thickness ≤ 5
             mm on transvaginal ultrasound (TVUS).

          -  Non-smokers.

          -  Negative test results for selected drugs of abuse and cotinine.

          -  Venous access sufficient to allow blood sampling as per the protocol.

          -  Subject is able to understand and comply with the protocol requirements, instructions,
             and protocol-stated restrictions.

          -  Subject has provided signed and dated written IC before participation in the study.

        Exclusion Criteria:

          -  For non-hysterectomized women: uterine disease or medical condition including:

               -  Bi-layer endometrial thickness &gt;5mm as determined by TVUS;

               -  Presence of fibroid(s) that obscure(s) evaluation of endometrium by TVUS;

               -  History or presence of uterine cancer;

               -  Presence of any significant uterine, ovarian or other adnexa related abnormality
                  as determined by TVUS;

               -  Presence of an endometrial polyp.

          -  Undiagnosed vaginal bleeding in the last 12 months.

          -  Any history of malignancy.

          -  History of venous or arterial thromboembolic disease

          -  Abnormal blood pressure.

          -  Use of :

               -  Any prescription drugs within 28 days prior to the first study dose
                  administration.

               -  Any over-the-counter (OTC) medication or dietary supplements (vitamins included)
                  within 14 days prior to the first study dose administration.

          -  Users of progestin implants or oestrogen alone injectable drug therapy are not allowed
             to participate unless treatment was stopped more than 3 months prior to screening.

          -  Users of oestrogen pellet or progestin injectable drug therapy are not allowed to
             participate unless treatment was stopped more than 6 months prior to screening.

          -  Subjects who are not in euthyroid condition.

          -  History of hypersensitivity or existing contraindication to E4 or intolerance to any
             component of the formulations or test meal.

          -  Presence or history of gallbladder disease, unless cholecystectomy has been performed.

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of drugs, or which may jeopardize the subject
             in case of participation in the study.

          -  History or presence of immunodeficiency diseases including a positive human
             immunodeficiency virus (HIV) test result, positive hepatitis B surface antigen (HBsAg)
             or hepatitis C test result.

          -  History of illicit drug or alcohol abuse within 12 months prior to first study dose or
             evidence of such abuse as indicated by laboratory values within 28 days prior to first
             study dose.

          -  Consumption of foods or beverages containing the following products during the
             specified timeframes prior to study drug administration in Period 1: caffeine or
             xanthine - 48 hours; alcohol - 48 hours; grapefruit/seville orange/citrus fruit and/or
             star fruit - 7 days. Others Fruit juices: 72 hours prior to study drug administration.

          -  Donation or loss of

               -  ≥ 450 mL blood within 1 month prior to initial study drug administration.

               -  ≥ 250 mL blood within 2 weeks prior to initial study drug administration.

          -  Sponsor, Contract Research Organization (CRO) or Investigator's site personnel or
             their relatives directly affiliated with this study.

          -  History or presence of clinically relevant disease of any major system organ class
             (SOC) (e.g. cardiovascular, pulmonary, renal, hepatic, gastrointestinal, reproductive,
             endocrinological, neurological, psychiatric or orthopedic disease) as judged by the
             Investigator.

          -  Previous completion or withdrawal from this study.

          -  Participation in another investigational drug clinical study within 1 month (30 days)
             or have received an investigational drug within the last 3 months (90 days) prior to
             study entry.

          -  Is judged by the Investigator to be unsuitable for any reason.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dobrin Svinarov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MC Comac Medical Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MC Comac Medical Ltd.</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 7, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2019</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Estetrol</keyword>
  <keyword>Menopausal hormone therapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

